Aptose Biosciences Inc (APTO)

[dcaf7]

Unfortunately, any strong data will be viewed as precursor of dilution. Therefore, no decent jump of SP. At best, Aptose is ~2 years away from the results of pivotal Ph2 study. Very long wait. Meanwhile, you will need to have expenses higher. They spent two valuable years and critically needed cash on Lux and APTO-253 but failed to deliver. Keep in mind that it was under favorable market conditions which you don't have here now. Second attempt will be much more painful. Pretty trivial story for a small biotech company. I am also not sure that Rice is a right CEO for challenging times that lie ahead. I can see only one good scenario, it is to be acquired.